ArticleBMC complementary medicine and therapies2022
Evaluation of anti-proliferative activity of Eryngium caucasicum on melanoma cancer cells.
Article in BMC complementary medicine and therapies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Solvent-Based Extraction Recovers Phytochemicals from Medicinal Plants Demonstrating Anticancer and Chemopreventive Potential: A Review.Molecules (Basel, Switzerland) · 2026Review
- Nonpolysaccharide fraction ofFrontiers in pharmacology · 2026Article
- Evaluation of Cytotoxic Activity of Cell Biomass fromMolecules (Basel, Switzerland) · 2024Article
- Macroscopical, Microscopical and Histochemical Analysis ofPlants (Basel, Switzerland) · 2023Article
- Ethnobotany, Biological Activities and Phytochemical Compounds of Some Species of the GenusMolecules (Basel, Switzerland) · 2023Review
- Anti-proliferative activity of Artemisia marschalliana on cancerous cell lines.BMC complementary medicine and therapies · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe genus Eryngium is a member of the Apiaceae family that has shown different pharmacological effects mainly including anti-inflammatory, analgesic, anti-cancer, hepatoprotective, and anti-oxidant. Previous research on the anti-cancer activity of Eryngium in some cancer cell lines has led us to explore the anti-proliferative activity of E. caucasicum in the B16F10 cell line.
objectiveIn this study, the antiproliferative activity of E. caucasicum on melanoma cancer cells (B16F10) and non-cancerous cells (HFFF2) were evaluated in vitro.
methodsThe dried plant sample of E. caucasicum was extracted by Soxhlet apparatus with n-Hexane, dichloromethane, and methanol solvents. The effects of cytotoxicity of the extracts by the MTT method on melanoma cancer cells (B16F10) and noncancerous cells (HFFF2) was investigated for 24 and 48 hours. Then, the cytotoxicity of different fractions of the strong extract against normal and cancer cells was evaluated by this method. Annexin V/PI assay was used to study the induction apoptosis via the fractions in cancer cells.
findingsAccording to the results of the MTT test, n-Hexane extract is the most effective extract against the B16F10 cell line and is a candidate for fractionation with VLC. Among the fractions, 40 and 60% VLC fractions of n-Hexan extract inhibited the growth of B16F10 cells at 24 and 48 hours while, these fractions at IC
conclusionThe n-Hexane extract of E. caucasicum and its 40 and 60% fractions showed the highest cytotoxic effect against the B16F10 cell line compared to other extracts and control groups. This inhibition was made through induction of apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.